Abstract 337P
Background
To determine the percentage of breast cancers detectable by fused diffusion-weighted imaging (DWI) using unenhanced magnetic resonance imaging (MRI) and abbreviated post-contrast-enhanced MRI.
Methods
Between October 2016 and October 2017, 194 consecutive women (mean age, 54.2 years; age range, 28-82 years) with newly diagnosed unilateral breast cancer who underwent preoperative 3.0 T breast MRI with DWI were evaluated. Both fused DWI and abbreviated MRI images were independently reviewed by two radiologists for the detection of index cancer (which showed the most suspicious findings in both breasts), location, lesion conspicuity, lesion type, and lesion size. Moreover, the relationship between cancer detection and histopathological results of surgical specimens were evaluated.
Results
Index cancer detection rates were comparable between fused DWI and abbreviated MRI (radiologist 1: 174/194 [89.7%] vs. 184/194 [94.8%], respectively, P = 0.057; radiologist 2: 174/194 [89.7%] vs. 183/194 [94.3%], respectively, P = 0.092). In both radiologists, abbreviated MRI showed a significantly higher lesion conspicuity than fused DWI (radiologist 1: 9.37 ± 2.24 vs. 8.78 ± 3.03, P < 0.001; radiologist 2: 9.16 ± 2.32 vs. 8.39 ± 2.93, P < 0.001). The κ value for the interobserver agreement of index cancer detection was 0.67 on fused DWI and 0.85 on abbreviated MRI. For lesion conspicuity, the intraclass correlation coefficients were 0.72 and 0.82 on fused DWI and abbreviated MRI, respectively. Among the histopathological factors, tumor invasiveness was associated with cancer detection on both fused DWI (P = 0.011) and abbreviated MRI (P = 0.004, radiologist 1), lymphovascular invasion was associated with cancer detection on abbreviated MRI (P = 0.032, radiologist 1), and necrosis was associated with cancer detection on fused DWI (P = 0.031, radiologist 2).
Conclusions
Index cancer detection was comparable between fused DWI and abbreviated MRI, although abbreviated MRI showed a significantly better lesion conspicuity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
333P - Evaluation of a composite PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant HER2-directed therapy in early breast cancer (TBCRC026)
Presenter: Maeve Hennessy
Session: Poster session 02
334P - The contribution of nurses in early detection of breast cancer in Cameroon
Presenter: Ngalla Calvin
Session: Poster session 02
335P - Real-world data: Correlation of radiological and pathologic complete response after neoadjuvant treatment of breast cancer
Presenter: Katarina Cular
Session: Poster session 02
336P - Dual-mode near-infrared multispectral imaging system equipped with deep learning models improves the identification of cancer foci in breast cancer specimens
Presenter: Yueping Liu
Session: Poster session 02